top of page
MedMira
Jul 14, 20223 min read
MedMira Strengthens and Expands Board
Halifax, Nova Scotia, 14 July, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Ms. Pascale Nini to the...
MedMira
Jun 5, 20224 min read
MedMira Receives Patent for its Unique Quantitative Diagnostic System
Halifax, Nova Scotia, June 6, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450)...
MedMira
May 26, 20222 min read
Update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
Halifax, Nova Scotia, 27 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe...
MedMira
May 19, 20222 min read
VYRAâ„¢ Product Line Update
Halifax, Nova Scotia, 20 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for...
MedMira
May 11, 20222 min read
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
Halifax, Nova Scotia, 12 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its...
MedMira
Mar 9, 20224 min read
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
Halifax, Nova Scotia, 9 March, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and...
MedMira
Mar 1, 20227 min read
Corporate update
In the second financial quarter of FY2022, MedMira continued its strategic plan to focus its own product portfolio on the two fastest...
MedMira
Feb 4, 20223 min read
MedMira Provides a Pre-Annual General Meeting Update
Halifax, Nova Scotia, 4 February, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on...
MedMira
Dec 21, 20212 min read
MedMira Announces VYRAâ„¢ CoV2Flu and Additional Regulatory Opportunities
Halifax, Nova Scotia, 21 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its VYRATMproduct line by...
MedMira
Dec 17, 20213 min read
MedMira strengthen its Board with New Appointment
Halifax, Nova Scotia, 17 December 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced today the appointment of Mr. Thomas Bergmann...
MedMira
Dec 14, 20212 min read
MedMira announces significant debt reduction and additional growth capital
Halifax, Nova Scotia, 14 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces a financial package of over $5.23 million...
MedMira
Jun 13, 20212 min read
Performance Update on World Health Organisation SARS-CoV2 Serology Standards
Halifax, Nova Scotia, 14 June, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the World Health Organization (WHO) SARS-CoV-2...
MedMira
Mar 3, 20212 min read
Product and Regulatory Update on MedMira’s COVID-19 Product Family
Halifax, Nova Scotia, 03 March, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its product portfolio and outlines...
MedMira
Jan 29, 20212 min read
Progress Update on MedMira’s COVID-19 Product Family
Halifax, Nova Scotia, 29 January, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test...
MedMira
Nov 30, 20202 min read
MedMira Announces Product Update
Halifax, Nova Scotia, 30 December, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR), is pleased to announce its validated REVEALCOVID-19™...
MedMira
Oct 6, 20202 min read
MedMira reports additional independent performance evaluation results of REVEALCOVID-19â„¢
Halifax, Nova Scotia, 7th of October, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the results of the latest independent...
MedMira
Apr 13, 20202 min read
MedMira Announces Update on Development of Point-of-Care Antibody Test
Halifax, Nova Scotia, 15th of April, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), announced today that it has completed the development of...
bottom of page